2-[18F]-Fluoro-2-deoxy-d-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx

European Journal of Surgical Oncology

Volumn 33, Issue 6, 2007, Pages 790-795

  Roh, J L ^a   Pae, K H ^a   Choi, S H ^a   Kim, J S ^a   Lee, S ^a   Kim, S B ^a   Nam, S Y ^a   Kim, S Y ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Hypopharynx; Larynx; Positron emission tomography; Predictive factor; Squamous cell carcinoma; Standardized uptake value

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EAR NOSE THROAT SURGERY; FEMALE; HUMAN; HYPOPHARYNX CARCINOMA; LARYNGECTOMY; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COHORT ANALYSIS; FOLLOW UP; FORECASTING; HYPOPHARYNX TUMOR; LARYNX TUMOR; MIDDLE AGED; PATIENT CARE PLANNING; SCINTISCANNING; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; FORECASTING; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT CARE PLANNING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34447097338     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.01.002     Document Type: Article

References (23)

1. Dimery I.W., and Hong W.K. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85 (1993) 95-111
2. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
3. Chiesa F., Mauri S., Tradati N., et al. Surfing prognostic factors in head and neck cancer at the millennium. Oral Oncol 35 (1999) 590-596
4. Wong R.J., Lin D.T., Schoder H., et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20 (2002) 4199-4208
5. Ryan W.R., Fee Jr. W.E., Le Q.T., and Pinto H.A. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 115 (2005) 645-650
6. Minn H., Lapela M., Klemi P.J., et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38 (1997) 1907-1911
7. Halfpenny W., Hain S.F., Biassoni L., Maisey M.N., Sherman J.A., and McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 86 (2002) 512-516
8. Allal A.S., Dulguerov P., Allaoua M., et al. Standardized uptake value of 2-[(18)F]fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20 (2002) 1398-1404
9. Kitagawa Y., Sadato N., Azuma H., et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med 40 (1999) 1132-1137
10. Brun E., Kjellen E., Tennvall J., et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24 (2002) 127-135
11. 18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys 59 (2004) 1295-1300
12. Schwartz D.L., Rajendran J., Yueh B., et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130 (2004) 1361-1367
13. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1690
14. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
15. Patronas N.J., Di Chiro G., Kufta C., et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62 (1985) 816-822
16. Ahuja V., Coleman R.E., Herndon J., and Patz Jr. E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83 (1998) 918-924
17. Swisher S.G., Erasmus J., Maish M., et al. 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101 (2004) 1776-1785
18. Okada J., Yoshikawa K., Itami M., et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33 (1992) 325-329
19. Suntharalingam M., Haas M.L., Van Echo D.A., et al. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91 (2001) 548-554
20. Urba S., Wolf G., Eisbruch A., et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 24 (2006) 593-598
21. Rewari A.N., Haffty B.G., Wilson L.D., et al. Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials. Cancer J 12 (2006) 123-129
22. Schuller D.E., Grecula J.C., Agrawal A., et al. Multimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx. Cancer 94 (2002) 3169-3178
23. Ozer E., Grecula J.C., Agrawal A., Rhoades C.A., Young D.C., and Schuller D.E. Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx. Laryngoscope 116 (2006) 607-612